Alexion to Acquire Antibody Specialist Syntimmune for US$1.2 B
By Michelle Liu
Pharma Deals Review: Vol 2018 Issue 9 (Table of Contents)
Published: 29 Sep-2018
DOI: 10.3833/pdr.v2018.i9.2361 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Just five months after its acquisition of Wilson Therapeutics, Alexion Pharmaceuticals is once again bulking up its pipeline with its latest acquisition of Syntimmune in a deal worth potentially up to US$1...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS